BNR Burning Rock Biotech Limited - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BNR Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Diagnostics & Research
Current Price
Live
$35.07
52W High
$41.72
52W Low
$2.18
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$377.58M
P/E
N/A
ROE
-20.2%
Profit margin
-22.5%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
The company exhibits a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe fundamental deterioration. Despite a strong gross margin of 73.02% and a healthy current ratio of 3.15, persistent unprofitability (negative ROE, ROA, and profit margin) and deeply negative earnings surprises over the past 12 quarters undermine any value proposition. The stock's recent 1Y price surge of +414.2% appears disconnected from fundamentals, especially given the lack of analyst coverage, no meaningful dividend, and deteriorating earnings trajectory. While the low debt/equity ratio is favorable, the absence of an Altman Z-Score and deeply negative Forward P/E (-60.47) signal high distress risk and speculative valuation.
Key Strengths
High gross margin (73.02%) indicates strong pricing power or low cost of goods sold
Healthy liquidity position with current ratio of 3.15 and quick ratio of 2.81
Low leverage with debt/equity ratio of only 0.06, reducing solvency risk
Recent short-term price momentum is strong (+414.2% over 1Y, +415.7% over 6M)
Operating in high-growth diagnostics & research sector with potential long-term tailwinds
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial weakness and poor earnings quality
Persistent unprofitability: negative profit margin (-22.48%), ROE (-20.25%), and ROA (-6.23%)
Consistently missing earnings estimates: 0/4 beats in last 4 quarters with average surprise of -25.09%
Extremely negative Forward P/E of -60.47 suggests no near-term profitability expectations
Lack of analyst coverage and target price data increases information asymmetry and risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
18
Weak
18
32
24
14
0
AI Verdict
High-risk speculative position with deteriorating fundamentals and no margin of safety
Key drivers: Piotroski F-Score of 1/9, Negative profitability across all metrics, Consistent earnings misses, Lack of analyst coverage, Recent price run-up disconnected from fundamentals
Confidence
82%
Value
18/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.70 is below sector average of 1.0+ (implied)
- Low debt enhances potential recovery value
Watchpoints
- Price/Book of 4.80 is high given negative earnings and ROE
- Forward P/E of -60.47 makes valuation meaningless
- No Graham Number or Intrinsic Value available
Future
32/100
Ref Growth rates
Positives
- YoY revenue growth of 2.30% shows minimal top-line expansion
- Sector tailwinds in diagnostics may support future growth
Watchpoints
- No earnings growth data available
- Negative Forward P/E implies no profitability in near term
- Q/Q EPS growth not sustainable given historical losses
Past
24/100
Ref Historical trends
Positives
- 52-week low of $2.18 suggests prior market capitulation
Watchpoints
- 12 consecutive quarters of earnings misses
- 5Y price change of -89.9% reflects long-term value destruction
- Historical ROE and margins consistently negative
Health
14/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 3.15 and quick ratio of 2.81 indicate short-term liquidity safety
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- No Altman Z-Score reported, increasing uncertainty
- ROIC unavailable, ROA and ROE deeply negative
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- No indication of future dividend plans
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$35.07
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BNR and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BNR
Burning Rock Biotech Limited
Primary
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
ABSI
Absci Corporation
Peer
|
-88.9% | +37.0% | -17.6% | -6.3% | -8.1% | +0.4% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-60.47
PEG Ratio
N/A
P/B Ratio
4.8
P/S Ratio
0.7
EV/Revenue
6.21
EV/EBITDA
-34.07
Market Cap
$377.58M
Profitability
Profit margins and return metrics
Profit Margin
-22.48%
Operating Margin
-12.26%
Gross Margin
73.02%
ROE
-20.25%
ROA
-6.23%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
3.15
Strong
Quick Ratio
2.81
Excellent
Cash/Share
$4.31
Quarterly Earnings History
EPS performance vs analyst estimates
2023-05-30
$-18.1
-30.2% surprise
2023-03-28
$-21.1
-11.1% surprise
2022-11-15
$-23.3
-23.9% surprise
2022-08-31
$-25.0
-35.1% surprise
Healthcare Sector Comparison
Comparing BNR against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-20.25%
This Stock
vs
-52.77%
Sector Avg
-61.6%
(Below Avg)
Profit Margin
-22.48%
This Stock
vs
-20.78%
Sector Avg
+8.2%
(Better)
Debt to Equity
0.06
This Stock
vs
6.16
Sector Avg
-99.0%
(Less Debt)
Revenue Growth
2.3%
This Stock
vs
137.39%
Sector Avg
-98.3%
(Slower)
Current Ratio
3.15
This Stock
vs
3.36
Sector Avg
-6.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | |
|
ABSI
Absci Corporation
|
BEARISH | $359.39M | - | -55.7% | -% | $2.39 | |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 |
Past News Coverage
Recent headlines mentioning BNR from our newsroom.
Newest → oldest
No matching news yet.